Peculiarities of community-acquired pneumonia treatment in patients with COVID-19
| Autor: | Nicolae Bacinschi, Ina Pogonea, Svetlana Chislaru, Carolina Catcov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Chlamydia medicine.drug_class business.industry Cephalosporin Bacterial pneumonia biochemical phenomena metabolism and nutrition medicine.disease respiratory tract diseases Pneumonia Community-acquired pneumonia Internal medicine polycyclic compounds medicine Sputum In patient Leukocytosis medicine.symptom business |
| Zdroj: | Bulletin of the Academy of Sciences of Moldova. Medical Sciences. 69 |
| ISSN: | 1857-0011 |
| DOI: | 10.52692/1857-0011.2021.1-69.22 |
| Popis: | The clinical picture (fever, cough, sputum, auscultatory changes), peripheral blood parameters (leukocytosis, ESR) and radiological data are currently the criteria for suspecting bacterial pneumonia in patients with SARS CoV-2 infection and for indication of antibacterial treatment. The initiation of antibiotic therapy is empirical by taking into account the pathogens most likely involved in community-acquired pneumonia (Str pneumoniae, St. aureus, Kl. pneumoniae, Haemofillus influenzae, Mecoplasma pneumoniae, Chlamydia, Ps. aeruginosa). Beta-lactams (cephalosporins, carbapenems), protected beta-lactams, macrolides and fluoroquinolones are the most commonly administered groups, and the combinations of cephalosporins + macrolides and cephalosporins + fluoroquinolones constitute the most used groups of antibacterial treatment in order to include bacterial flora, gram-positive or gram-negative, and atypical. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|